Board member in Xspray Pharma acquires shares from the CEO

Press release 2023-03-13

Anders Bladh, board member of Xspray Pharma, through his company Ribbskottet AB, has acquired 30,000 shares in Xspray Pharma from the CEO Per Andersson.

Xspray Pharma's CEO Per Andersson has sold 30,000 shares in Xspray Pharma, on March 13, 2023, to Board Member of Xspray Pharma, Anders Bladh via his company Ribbskottet AB. The transaction was completed outside stock market trading at a share price of SEK 72.00.

Ribbskottet increases its ownership to 2,480,000 shares. The traded shares constitute a minor part of Per Andersson’s holdings, totalling 212,294 after the transaction. The sale is due to private financial reasons.

“My holding in Xspray remains my single largest private financial investment by far. My commitment and strong belief in Xspray's future remains and I look forward to continuing leading and developing Xspray towards market launch and commercialization,” says Per Andersson, CEO of Xspray Pharma.

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com